Credit Suisse Group reiterated their outperform rating on shares of Quintiles Transitional Holdings Inc. (NYSE:Q) in a report published on Tuesday morning. They currently have a $125.00 price target on the medical research company’s stock, up from their previous price target of $115.00.
Other equities research analysts have also recently issued research reports about the stock. Barclays PLC restated an overweight rating and set a $98.00 target price (up previously from $90.00) on shares of Quintiles Transitional Holdings in a research note on Monday, July 17th. Stifel Nicolaus upgraded shares of Quintiles Transitional Holdings from a hold rating to a buy rating and raised their target price for the stock from $92.00 to $128.00 in a research note on Friday, October 27th. William Blair upgraded shares of Quintiles Transitional Holdings from a market perform rating to an outperform rating and raised their target price for the stock from $70.10 to $93.42 in a research note on Friday, August 4th. Jefferies Group LLC restated a hold rating and set a $94.00 target price on shares of Quintiles Transitional Holdings in a research note on Friday, August 4th. Finally, Citigroup Inc. raised their target price on shares of Quintiles Transitional Holdings from $96.00 to $97.00 and gave the stock a neutral rating in a research note on Monday, August 7th. Eight investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Buy and an average price target of $101.64.
Quintiles Transitional Holdings (NYSE:Q) traded down 0.35% during mid-day trading on Tuesday, hitting $107.72. 413,796 shares of the stock traded hands. Quintiles Transitional Holdings has a 1-year low of $70.10 and a 1-year high of $109.00. The stock has a market cap of $23.32 billion, a price-to-earnings ratio of 312.23 and a beta of 0.62. The company’s 50 day moving average price is $98.22 and its 200-day moving average price is $91.01.
Quintiles Transitional Holdings (NYSE:Q) last released its earnings results on Thursday, October 26th. The medical research company reported $1.19 EPS for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. Quintiles Transitional Holdings had a net margin of 0.58% and a return on equity of 12.60%. The company had revenue of $2.02 billion for the quarter, compared to analysts’ expectations of $2.01 billion. During the same quarter last year, the business earned $1.00 EPS. The firm’s revenue was up 77.6% compared to the same quarter last year. Analysts predict that Quintiles Transitional Holdings will post $4.61 earnings per share for the current year.
In related news, Director Dennis B. Ph D. Gillings sold 968,023 shares of the business’s stock in a transaction on Monday, August 28th. The shares were sold at an average price of $97.33, for a total value of $94,217,678.59. Following the sale, the director now owns 9,071,839 shares in the company, valued at $882,962,089.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ari Bousbib sold 92,160 shares of the business’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $90.35, for a total transaction of $8,326,656.00. Following the completion of the sale, the insider now owns 1,082,919 shares in the company, valued at approximately $97,841,731.65. The disclosure for this sale can be found here. Insiders sold 14,208,382 shares of company stock worth $1,362,839,475 in the last 90 days. 6.40% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in Q. Prudential Financial Inc. increased its position in Quintiles Transitional Holdings by 24.6% in the first quarter. Prudential Financial Inc. now owns 18,721 shares of the medical research company’s stock worth $1,508,000 after purchasing an additional 3,700 shares during the last quarter. FMR LLC increased its position in Quintiles Transitional Holdings by 11.2% in the first quarter. FMR LLC now owns 215,936 shares of the medical research company’s stock worth $17,389,000 after purchasing an additional 21,742 shares during the last quarter. Teachers Advisors LLC increased its position in Quintiles Transitional Holdings by 23.6% in the first quarter. Teachers Advisors LLC now owns 381,161 shares of the medical research company’s stock worth $30,695,000 after purchasing an additional 72,728 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Quintiles Transitional Holdings by 43.9% in the first quarter. Dimensional Fund Advisors LP now owns 609,628 shares of the medical research company’s stock worth $49,089,000 after purchasing an additional 186,027 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Quintiles Transitional Holdings in the first quarter worth $4,957,000. Institutional investors own 93.03% of the company’s stock.
Quintiles Transitional Holdings Company Profile
Quintiles IMS Holdings, Inc, formerly Quintiles Transnational Holdings Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
What are top analysts saying about Quintiles Transitional Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quintiles Transitional Holdings Inc. and related companies.